Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Navidea Biopharmaceuticals Inc (NY: NAVB ) N/A UNCHANGED Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Navidea Biopharmaceuticals Inc < Previous 1 2 3 4 5 6 Next > Earnings Scheduled For August 11, 2021 August 11, 2021 Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter. • Gamida Cell (NASDAQ:GMDA) is... Via Benzinga The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight August 08, 2021 Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... Via Benzinga Exposures Product Safety Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update August 04, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire Earnings Scheduled For May 11, 2021 May 11, 2021 Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is... Via Benzinga Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications July 19, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Stock Gains After FDA Grants End Of Phase 2 Meeting To Discuss Rheumatoid Arthritis Program July 15, 2021 The FDA has granted Navidea Biopharmaceuticals Inc's (NYSE: NAVB) request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in... Via Benzinga Exposures Product Safety Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis July 15, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty June 24, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections May 19, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results May 11, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces NIH Grant Award to UC San Diego for Clinical Study Evaluating Tc99m Tilmanocept as a Kidney Imaging Agent May 11, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings May 11, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... Via Benzinga Exposures COVID-19 Product Safety The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings May 09, 2021 Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... Via Benzinga Exposures COVID-19 Product Safety Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition May 05, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update May 04, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire Navidea Biopharmaceuticals Announces Acceptance of Therapeutics Focused Abstract for Presentation at the Frontiers in Cancer Immunotherapy Symposium April 15, 2021 From Navidea Biopharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
